Shots: The ongoing two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 evaluating CTX001 in 45 patients with a follow-up of ~2yrs. after infusion aged 18-35yrs to treat transfusion-dependent beta-thalassemia & sickle […]readmore
Tags : CTX001
Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 […]readmore
Shots: The two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 studies will assess CTX001 in patients with transfusion-dependent beta-thalassemia & sickle cell disease aged 18-35yrs. and enrolls up to 45 patients […]readmore